Society of Nuclear Medicine Offers Online CME

Leveraging Biology to Advance the Small Cell Lung Cancer Treatment Paradigm

Approximately half of the patients who received raludotatug deruxtecan in the phase 2/3 REJOICE-Ovarian01 trial achieved an objective response.

Anne Chiang, MD

FDA Accepts Resubmission of BLA for RP1/Nivolumab in Advanced Melanoma

“Paradigm-changing events” are occurring across the small cell lung cancer field in real time, according to Anne Chiang, MD, PhD.

A Prescription Drug User Fee Act date of April 10, 2026, has been established by the FDA based on a Class II resubmission timeline.

Tim Cortese

Exploring the ESMO 2025 Presentations That May Shift GU Oncology

The agency has set a PDUFA date of April 10, 2026, for the decision on RP1 plus nivolumab in patients with previously treated advanced melanoma.

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD

October 16th 2025

Nivolumab/Ipilimumab Maintain PFS Benefit vs Nivolumab Monotherapy in MSI-H/dMMR CRC

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

• Nivolumab plus ipilimumab continued to show clinically meaningful PFS improvement over nivolumab alone in MSI-H/dMMR mCRC.

Kristie L. Kahl

Bemarituzumab Regimen Prolongs Survival in Advanced Gastric/GEJ Cancer

With a median follow-up of 50.1 months, nivolumab plus ipilimumab achieved a median PFS of not reached compared with 60.8 months with nivolumab monotherapy in this CRC population.

The overall survival benefit with the bemarituzumab combination in the phase 3 FORTITUDE-101 trial was consistent across key prespecified subgroups.

Ashling Wahner

Raludotatug Deruxtecan Shows Promise in Platinum-Resistant Ovarian Cancer

The overall survival benefit with the bemarituzumab combination in the phase 3 FORTITUDE-101 trial was consistent across key prespecified subgroups.

Related Content

Jason M. Broderick

Leveraging Biology to Advance the Small Cell Lung Cancer Treatment Paradigm

Approximately half of the patients who received raludotatug deruxtecan in the phase 2/3 REJOICE-Ovarian01 trial achieved an objective response.

Anne Chiang, MD

FDA Accepts Resubmission of BLA for RP1/Nivolumab in Advanced Melanoma

“Paradigm-changing events” are occurring across the small cell lung cancer field in real time, according to Anne Chiang, MD, PhD.

Tim Cortese

Exploring the ESMO 2025 Presentations That May Shift GU Oncology

The agency has set a PDUFA date of April 10, 2026, for the decision on RP1 plus nivolumab in patients with previously treated advanced melanoma.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD

October 16th 2025

Nivolumab/Ipilimumab Maintain PFS Benefit vs Nivolumab Monotherapy in MSI-H/dMMR CRC

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Kristie L. Kahl

Bemarituzumab Regimen Prolongs Survival in Advanced Gastric/GEJ Cancer

With a median follow-up of 50.1 months, nivolumab plus ipilimumab achieved a median PFS of not reached compared with 60.8 months with nivolumab monotherapy in this CRC population.

Ashling Wahner